ReviewCA: a cancer journal for clinicians
Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine.
Review in CA: a cancer journal for clinicians. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 139 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
139 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Public Preferences for Emerging Cancer Screening Modalities: A Systematic Review of Discrete Choice Experiments.The patient · 2026Pooled it
- Cancer Predisposition Genes in Adolescents and Young Adults (AYAs): a Review Paper from the Italian AYA Working Group.Current oncology reports · 2022Pooled it
- Primary care providers' cancer genetic testing-related knowledge, attitudes, and communication behaviors: A systematic review and research agenda.Journal of general internal medicine · 2017Pooled it
- Oncogenetics training in Brazilian medical genetics residency programs: current landscape and challenges.Journal of community genetics · 2026Article
- Managing Refractory Pericarditis in the Era of Biologic Therapy: A Cardio-Oncology-Based Risk Framework.JACC. Advances · 2026Article
- Germline DDX41 mutations in myeloid neoplasms: a comprehensive review.The Korean journal of internal medicine · 2026Review
- Economic Evaluation of GARDE: A Digital Health Platform for Population-Level Hereditary Cancer Risk Assessment.JCO oncology practice · 2026Article
- Independent factors associated with advanced testicular germ cell tumors: the roles of smoking, lymphovascular invasion, and tumor size.BMC cancer · 2026Article
- Genome doubling as a dynamic driver of ovarian cancer evolution: insights from single-cell sequencing.Journal of ovarian research · 2025Review
- Integration of exosome-related genes and differential expression analysis reveals potential biomarkers for prostate cancer.Discover oncology · 2025Article
- Deciphering and targeting oncogenic pathways through integrated approaches and amino acid metabolism in hematologic malignancies.Discover oncology · 2025Review
- XGB-BIF: An XGBoost-Driven Biomarker Identification Framework for Detecting Cancer Using Human Genomic Data.International journal of molecular sciences · 2025Article
- Genetic counselors' and community clinicians' implementation and perceived barriers to informed consent during pre-test counseling for hereditary cancer risk.Journal of genetic counseling · 2025Article
- Early and hereditary breast cancer: advances in risk stratification and imaging approaches.Therapeutic advances in medical oncology · 2025Review
- Understanding Genetic Screening: Harnessing Health Information to Prevent Disease Risks.International journal of medical sciences · 2025Review
- Precision medicine in breast cancer (Review).Molecular and clinical oncology · 2024Review
- Uptake of Risk-Reducing Surgeries in an International Real-World Cohort of Hispanic Women.JCO global oncology · 2024Article
- Poor compliance with germline testing recommendations in colorectal cancer patients undergoing molecular residual disease testing.Communications medicine · 2024Article
- Bridging the Divide: A Review on the Implementation of Personalized Cancer Medicine.Journal of personalized medicine · 2024Review
- Themis: advancing precision oncology through comprehensive molecular subtyping and optimization.Briefings in bioinformatics · 2024Article
79 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Scientific and technologic advances are revolutionizing our approach to genetic cancer risk assessment, cancer screening and prevention, and targeted therapy, fulfilling the promise of personalized medicine. In this monograph, we review the evolution of scientific discovery in cancer genetics and genomics, and describe current approaches, benefits, and barriers to the translation of this information to the practice of preventive medicine. Summaries of known hereditary cancer syndromes and highly penetrant genes are provided and contrasted with recently discovered genomic variants associated with modest increases in cancer risk. We describe the scope of knowledge, tools, and expertise required for the translation of complex genetic and genomic test information into clinical practice. The challenges of genomic counseling include the need for genetics and genomics professional education and multidisciplinary team training, the need for evidence-based information regarding the clinical utility of testing for genomic variants, the potential dangers posed by premature marketing of first-generation genomic profiles, and the need for new clinical models to improve access to and responsible communication of complex disease risk information. We conclude that given the experiences and lessons learned in the genetics era, the multidisciplinary model of genetic cancer risk assessment and management will serve as a solid foundation to support the integration of personalized genomic information into the practice of cancer medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.